InvestorsHub Logo
Followers 57
Posts 11397
Boards Moderated 0
Alias Born 02/09/2009

Re: None

Thursday, 12/08/2022 10:04:48 AM

Thursday, December 08, 2022 10:04:48 AM

Post# of 547
6 Dec 2022 News Release

https://www.businesswire.com/news/home/20221206005205/en/

Two important things (of many):

1) Selective inhibition of TNF-alpha
2) Oral administration

The reduction of inflammation compared to a widely prescribed biologic may not be as great as some had hoped.

What the NR does not cover is the harm not done by MYMD-1 compared to the (and all similar) biologic.

"Harm Not Done" should become a major selling point.

MYMD-1 is a jeweler's hammer, harmlessly doing only what's needed; Currently prescribed biologics are a wrecking ball, doing what's needed, but also doing a lot that's harmful.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMD News